Rhumbline Advisers Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

Rhumbline Advisers boosted its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 13.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 597,467 shares of the company's stock after purchasing an additional 72,464 shares during the quarter. Rhumbline Advisers owned approximately 0.15% of Moderna worth $16,938,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in shares of Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after acquiring an additional 388 shares in the last quarter. Caprock Group LLC purchased a new stake in Moderna in the fourth quarter worth $203,000. abrdn plc increased its stake in Moderna by 28.1% in the fourth quarter. abrdn plc now owns 315,912 shares of the company's stock worth $12,842,000 after purchasing an additional 69,360 shares during the period. Yousif Capital Management LLC grew its position in shares of Moderna by 3.9% during the 4th quarter. Yousif Capital Management LLC now owns 42,171 shares of the company's stock worth $1,753,000 after buying an additional 1,568 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its position in shares of Moderna by 1.9% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 34,863 shares of the company's stock worth $1,450,000 after buying an additional 657 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

Shares of Moderna stock traded up $0.07 during trading hours on Wednesday, hitting $27.75. The company's stock had a trading volume of 9,189,281 shares, compared to its average volume of 8,347,804. The firm has a fifty day moving average of $26.21 and a 200-day moving average of $33.28. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $150.74. The stock has a market cap of $10.73 billion, a price-to-earnings ratio of -2.99 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business's quarterly revenue was down 35.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.07) earnings per share. On average, sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MRNA. Citigroup started coverage on Moderna in a research report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective on the stock. William Blair restated a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Barclays reduced their price target on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. JPMorgan Chase & Co. cut their price objective on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a research report on Thursday, May 22nd. Finally, Royal Bank of Canada lowered their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Moderna presently has a consensus rating of "Hold" and a consensus price target of $53.58.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.